SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/12/13 Biolase, Inc 10-Q 9/30/13 65:8.2M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 543K 2: EX-4 Ex-4.2 HTML 65K 3: EX-4 Ex-4.3 HTML 63K 4: EX-10 Ex-10.4 HTML 47K 5: EX-31 Ex-31.1 HTML 27K 6: EX-31 Ex-31.2 HTML 28K 7: EX-32 Ex-32.1 HTML 21K 8: EX-32 Ex-32.2 HTML 22K 64: R1 Document and Entity Information HTML 41K 45: R2 Consolidated Balance Sheets HTML 136K 42: R3 Consolidated Balance Sheets (Parenthetical) HTML 48K 17: R4 Consolidated Statements Of Operations And HTML 105K Comprehensive Loss 44: R5 Consolidated Statements Of Cash Flows HTML 144K 31: R6 Basis of Presentation HTML 55K 57: R7 Recent Accounting Pronouncements HTML 30K 32: R8 Stock-Based Awards and Per Share Information HTML 222K 34: R9 Inventory HTML 37K 18: R10 Property, Plant, and Equipment HTML 53K 33: R11 Intangible Assets and Goodwill HTML 101K 56: R12 Accrued Liabilities and Deferred Revenue HTML 110K 52: R13 Lines Of Credit and Other Borrowings HTML 55K 43: R14 Commitments and Contingencies HTML 42K 61: R15 Segment Information HTML 56K 55: R16 Concentrations HTML 28K 15: R17 Income Taxes HTML 41K 20: R18 Subsequent Event HTML 22K 60: R19 Accounting Policies (Policies) HTML 114K 63: R20 Stock-Based Awards and Per Share Information HTML 192K (Tables) 65: R21 Inventory (Tables) HTML 34K 62: R22 Property, Plant, and Equipment (Tables) HTML 49K 47: R23 Intangible Assets and Goodwill (Tables) HTML 93K 19: R24 Accrued Liabilities and Deferred Revenue (Tables) HTML 116K 30: R25 Segment Information (Tables) HTML 47K 23: R26 Basis of Presentation - Additional Information HTML 67K (Detail) 22: R27 Classification of Compensation Expense Associated HTML 29K with Share-Based Payments (Detail) 36: R28 Assumptions Used in Estimating Fair Value of Stock HTML 32K Options Granted (Detail) 46: R29 Summary of Option Activity (Detail) HTML 72K 53: R30 Cash Proceeds Along with Fair Value Disclosures HTML 39K Related to grants Exercises and Vesting Options (Detail) 27: R31 Stock Based Awards and Per Share Information - HTML 115K Additional Information (Detail) 37: R32 Components of Inventory (Detail) HTML 32K 59: R33 Inventory - Additional Information (Detail) HTML 25K 25: R34 Summary of Property, Plant, and Equipment (Detail) HTML 36K 50: R35 Property, Plant, and Equipment - Additional HTML 22K Information (Detail) 51: R36 Intangible Assets Related to Accumulated HTML 52K Amortization and Goodwill (Detail) 38: R37 Intangible Assets and Goodwill - Additional HTML 24K Information (Detail) 21: R38 Components of Accrued Liabilities (Detail) HTML 43K 49: R39 Changes In Initial Product Warranty Accrual and HTML 38K Expenses Under Initial and Extended Warranties (Detail) 26: R40 Summary of Deferred Revenue (Detail) HTML 37K 35: R41 Lines of Credit and Other Borrowings - Additional HTML 111K Information (Detail) 54: R42 Commitments and Contingencies - Additional HTML 32K Information (Detail) 29: R43 Summary of Net Revenue by Geographic Location HTML 24K (Detail) 48: R44 Segment Information - Additional Information HTML 30K (Detail) 41: R45 Concentrations - Additional Information (Detail) HTML 31K 24: R46 Income Taxes - Additional Information (Detail) HTML 57K 58: R47 Subsequent Event - Additional Information (Detail) HTML 21K 40: XML IDEA XML File -- Filing Summary XML 91K 16: EXCEL IDEA Workbook of Financial Reports XLSX 134K 39: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 1.26M 9: EX-101.INS XBRL Instance -- biol-20130930 XML 1.59M 11: EX-101.CAL XBRL Calculations -- biol-20130930_cal XML 132K 12: EX-101.DEF XBRL Definitions -- biol-20130930_def XML 710K 13: EX-101.LAB XBRL Labels -- biol-20130930_lab XML 998K 14: EX-101.PRE XBRL Presentations -- biol-20130930_pre XML 800K 10: EX-101.SCH XBRL Schema -- biol-20130930 XSD 161K 28: ZIP XBRL Zipped Folder -- 0001564590-13-001200-xbrl Zip 135K
Exhibit 32.1
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of BIOLASE, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Federico Pignatelli, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(i) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 12, 2013 |
|
|
|
|
Chief Executive Officer (Principal Executive Officer) |
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 11/12/13 | 8-K | ||
For Period end: | 9/30/13 | |||
List all Filings |